Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials

Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials

1.Lee, A. K. et al. The Association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 41, 104–111. https://doi.org/10.2337/dc17-1669 (2018).Article 
PubMed 

Google Scholar 
2.Aucott, L. S. et al. Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study. BMJ Open 6, e010836. https://doi.org/10.1136/bmjopen-2015-010836 (2016).Article 
PubMed 
PubMed Central 

Google Scholar 
3.Kanters, S. D., Banga, J. D., Stolk, R. P. & Algra, A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc. Med. 4, 67–75. https://doi.org/10.1177/1358836×9900400203 (1999).CAS 
Article 
PubMed 

Google Scholar 
4.Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139. https://doi.org/10.1056/NEJMoa0808431 (2009).CAS 
Article 
PubMed 

Google Scholar 
5.Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559. https://doi.org/10.1056/NEJMoa0802743 (2008).CAS 
Article 
PubMed 

Google Scholar 
6.Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572. https://doi.org/10.1056/NEJMoa0802987 (2008).CAS 
Article 
PubMed 

Google Scholar 
7.Turner, R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854–865 (1998).8.Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322. https://doi.org/10.1056/NEJMoa1603827 (2016).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
9.Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128. https://doi.org/10.1056/NEJMoa1504720 (2015).CAS 
Article 
PubMed 

Google Scholar 
10.Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657. https://doi.org/10.1056/NEJMoa1611925 (2017).CAS 
Article 
PubMed 

Google Scholar 
11.Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844. https://doi.org/10.1056/NEJMoa1607141 (2016).CAS 
Article 
PubMed 

Google Scholar 
12.12Association, A. D. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 (2020). doi:10.2337/dc20-S00913.Pfeffer, M. A. et al. Lixisenatide in patients with type 2
diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257. https://doi.org/10.1056/NEJMoa1509225 (2015).CAS 
Article 
PubMed 

Google Scholar 
14.Ratner, R. et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc. Diabetol. 10, 22. https://doi.org/10.1186/1475-2840-10-22 (2011).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
15.Davies, M. J. , & Management of Hyperglycemia in Type 2 Diabetes, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41(2669–2701), 2018. https://doi.org/10.2337/dci18-0033 (2018).Article 

Google Scholar 
16.Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535. https://doi.org/10.1136/bmj.b2535 (2009).Article 
PubMed 
PubMed Central 

Google Scholar 
17.17Higgins, J. P. T. & Green, S. Cochrane handbook for systematic reviews of interventions. In The Cochrane Collaboration (2011).18.Higgins, J. P. et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928. https://doi.org/10.1136/bmj.d5928 (2011).Article 
PubMed 
PubMed Central 

Google Scholar 
19.19GRADEpro GDT: GRADEpro Guideline Development Tool [Software] (2015). https://gradepro.org.20.Turner, R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).21.Begg, C. B. & Berlin, J. A. Publication bias: a problem in interpreting medical data. J. R. Stat. Soc. Ser. A (Stat. Soc.) 151, 419–463. https://doi.org/10.2307/2982993 (1988).Article 

Google Scholar 
22.Sterne, J. A. C., Egger, M. & Smith, G. D. Investigating and dealing with publication and other biases in meta-analysis. BMJ 323, 101–105 (2001).CAS 
Article 

Google Scholar 
23.23Borenstein, M., Hedges, L. V., Higgins, J. P. T. & Rothstein, H. R. In Introduction to Meta‐Analysis Vol. 1 Ch. 21 (Wiley, 2009).24.Kahn, S. E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443. https://doi.org/10.1056/NEJMoa066224 (2006).CAS 
Article 
PubMed 

Google Scholar 
25.Pratley, R. et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet https://doi.org/10.1016/s0140-6736(19)31271-1 (2019).Article 
PubMed 

Google Scholar 
26.Holman, R. R. et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N. Engl. J. Med. 361, 1736–1747. https://doi.org/10.1056/NEJMoa0905479 (2009).CAS 
Article 
PubMed 

Google Scholar 
27.Gilbert, R. E. & Krum, H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385, 2107–2117. https://doi.org/10.1016/s0140-6736(14)61402-1 (2015).CAS 
Article 
PubMed 

Google Scholar 
28.Hanefeld, M., Frier, B. M. & Pistrosch, F. Hypoglycemia and cardiovascular risk: is there a major link?. Diabetes Care 39(Suppl 2), S205-209. https://doi.org/10.2337/dcS15-3014 (2016).CAS 
Article 
PubMed 

Google Scholar 
29.Kernan, W. N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321–1331. https://doi.org/10.1056/NEJMoa1506930 (2016).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
30.Rundek, T. et al. Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study. Arch. Neurol. 67, 1195–1200. https://doi.org/10.1001/archneurol.2010.235 (2010).Article 
PubMed 
PubMed Central 

Google Scholar 
31.Palmer, S. C. et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316, 313–324. https://doi.org/10.1001/jama.2016.9400 (2016).CAS 
Article 
PubMed 

Google Scholar 
32.Zheng, S. L. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319, 1580–1591. https://doi.org/10.1001/jama.2018.3024 (2018).ADS 
CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
33.Wu, S. et al. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis. Expert Opin. Drug. Saf. 17, 243–249. https://doi.org/10.1080/14740338.2018.1424826 (2018).CAS 
Article 
PubMed 

Google Scholar 
34.Liu, J. et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 357, j2499. https://doi.org/10.1136/bmj.j2499 (2017).Article 
PubMed 
PubMed Central 

Google Scholar 
35.Tang, H. et al. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am. J. Cardiol. 118, 1774–1780. https://doi.org/10.1016/j.amjcard.2016.08.061 (2016).CAS 
Article 
PubMed 

Google Scholar 
36.Boussageon, R. et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 9, e1001204. https://doi.org/10.1371/journal.pmed.1001204 (2012).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
37.Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 379, 633–644. https://doi.org/10.1056/NEJMoa1800256 (2018).Article 
PubMed 

Google Scholar 
38.Gregg, E. W. et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 4, 913–921. https://doi.org/10.1016/s2213-8587(16)30162-0 (2016).Article 
PubMed 
PubMed Central 

Google Scholar 
39.Inzucchi, S. E. et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41, 356–363. https://doi.org/10.2337/dc17-1096 (2018).CAS 
Article 
PubMed 

Google Scholar 
40.Pc, L., Aj, S., Kr, A. & Dr, J. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J. Clin. Epidemiol. https://doi.org/10.1016/s0895-4356(01)00414-0 (2002).Article 

Google Scholar 
41.Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366, 1279–1289. https://doi.org/10.1016/s0140-6736(05)67528-9 (2005).CAS 
Article 
PubMed 

Google Scholar 
42.Mazzone, T. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296, 2572–2581. https://doi.org/10.1001/jama.296.21.joc60158 (2006).CAS 
Article 
PubMed 

Google Scholar 
43.Nauck, M. A., Meininger, G., Sheng, D., Terranella, L. & Stein, P. P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 9, 194–205. https://doi.org/10.1111/j.1463-1326.2006.00704.x (2007).CAS 
Article 
PubMed 

Google Scholar 
44.Dargie, H. J. et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J. Am. Coll. Cardiol. 49, 1696–1704. https://doi.org/10.1016/j.jacc.2006.10.077 (2007).CAS 
Article 
PubMed 

Google Scholar 
45.Chan, J. C. et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 10, 545–555. https://doi.org/10.1111/j.1463-1326.2008.00914.x (2008).CAS 
Article 
PubMed 

Google Scholar 
46.Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373, 2125–2135. https://doi.org/10.1016/s0140-6736(09)60953-3 (2009).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
47.Kooy, A. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169, 616–625. https://doi.org/10.1001/archinternmed.2009.20 (2009).CAS 
Article 
PubMed 

Google Scholar 
48.Bertrand, O. F. et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis 211, 565–573. https://doi.org/10.1016/j.atherosclerosis.2010.06.005 (2010).CAS 
Article 
PubMed 

Google Scholar 
49.Gaziano, J. M. et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33, 1503–1508. https://doi.org/10.2337/dc09-2009 (2010).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
50.Giles, T. D., Elkayam, U., Bhattacharya, M., Perez, A. & Miller, A. B. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest. Heart Fail. 16, 111–117. https://doi.org/10.1111/j.1751-7133.2010.00154.x (2010).CAS 
Article 
PubMed 

Google Scholar 
51.Matthews, D. R. et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes. Metab. 12, 780–789. https://doi.org/10.1111/j.1463-1326.2010.01233.x (2010).CAS 
Article 
PubMed 

Google Scholar 
52.Gallwitz, B. et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 379, 2270–2278. https://doi.org/10.1016/s0140-6736(12)60479-6 (2012).CAS 
Article 
PubMed 

Google Scholar 
53.Gallwitz, B. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380, 475–483. https://doi.org/10.1016/s0140-6736(12)60691-6 (2012).CAS 
Article 
PubMed 

Google Scholar 
54.Garber, A. J. et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379, 1498–1507. https://doi.org/10.1016/s0140-6736(12)60205-0 (2012).CAS 
Article 
PubMed 

Google Scholar 
55.Gerstein, H. C. et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319–328. https://doi.org/10.1056/NEJMoa1203858 (2012).CAS 
Article 
PubMed 

Google Scholar 
56.Zinman, B. et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 35, 2464–2471. https://doi.org/10.2337/dc12-1205 (2012).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
57.Cefalu, W. T. et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382, 941–950. https://doi.org/10.1016/s0140-6736(13)60683-2 (2013).CAS 
Article 
PubMed 

Google Scholar 
58.Hong, J. et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36, 1304–1311. https://doi.org/10.2337/dc12-0719 (2013).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
59.Scirica, B. M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326. https://doi.org/10.1056/NEJMoa1307684 (2013).CAS 
Article 
PubMed 

Google Scholar 
60.White, W. B. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327–1335. https://doi.org/10.1056/NEJMoa1305889 (2013).CAS 
Article 
PubMed 

Google Scholar 
61.Ridderstrale, M. et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2, 691–700. https://doi.org/10.1016/s2213-8587(14)70120-2 (2014).Article 
PubMed 

Google Scholar 
62.Blonde, L. et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 385, 2057–2066. https://doi.org/10.1016/s0140-6736(15)60936-9 (2015).CAS 
Article 
PubMed 

Google Scholar 
63.Giorgino, F., Benroubi, M., Sun, J. H., Zimmermann, A. G. & Pechtner, V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (award-2). Diabetes Care 38, 2241–2249. https://doi.org/10.2337/dc14-1625 (2015).CAS 
Article 
PubMed 

Google Scholar 
64.Green, J. B. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232–242. https://doi.org/10.1056/NEJMoa1501352 (2015).ADS 
CAS 
Article 
PubMed 

Google Scholar 
65.Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239. https://doi.org/10.1056/NEJMoa1612917 (2017).CAS 
Article 
PubMed 

Google Scholar 
66.Marso, S. P. et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N. Engl. J. Med. 377, 723–732. https://doi.org/10.1056/NEJMoa1615692 (2017).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
67.Vaccaro, O. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 10, 15–20. https://doi.org/10.1016/s2213-8587(17)30317-0 (2017).Article 

Google Scholar 
68.Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529. https://doi.org/10.1016/s0140-6736(18)32261-x (2018).CAS 
Article 
PubMed 

Google Scholar 
69.Rosenstock, J. et al. Effect of Linagliptin vs Placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321, 69–79. https://doi.org/10.1001/jama.2018.18269 (2019).CAS 
Article 
PubMed 
PubMed Central 

Google Scholar 
70.Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet https://doi.org/10.1016/s0140-6736(19)31149-3 (2019).Article 
PubMed 

Google Scholar 
71.Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1901118 (2019).Article 
PubMed 

Google Scholar 
72.Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306. https://doi.org/10.1056/NEJMoa1811744 (2019).CAS 
Article 
PubMed 

Google Scholar 
73.Pieber, T. R. et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 7, 528–539. https://doi.org/10.1016/s2213-8587(19)30194-9 (2019).CAS 
Article 
PubMed 

Google Scholar 
74.Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357. https://doi.org/10.1056/NEJMoa1812389 (2019).CAS 
Article 
PubMed 

Google Scholar 
75.Rosenstock, J. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA https://doi.org/10.1001/jama.2019.13772 (2019).Article 
PubMed 
PubMed Central 

Google Scholar 

Via Source link